<DOC>
	<DOCNO>NCT00643851</DOCNO>
	<brief_summary>The purpose clinical research study learn initiate treatment BMS-51248 ( Dapagliflozin ) combination metformin XR improve diabetes control patient Type 2 Diabetes receive pharmacological treatment diabetes , compare initial treatment monotherapy dapagliflozin metformin XR . The safety treatment also study</brief_summary>
	<brief_title>An Efficacy &amp; Safety Study BMS-512148 Combination With Metformin Extended Release Tablets</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Males &amp; female , 1877 year old inclusive , type 2 diabetes inadequate glycemic control Drug naive treat antidiabetic medication &lt; 24 week since original diagnosis Cpeptide ≥ 1.0 ng/mL Body Mass Index ≤ 45.0 kg/m Serum creatinine &lt; 1.50 mg/dL men &lt; 1.40 mg/dL woman AST and/or ALT &gt; 3.0 time upper limit normal ( ULN ) Serum total bilirubin &gt; 2.0 mg/dL Creatine kinase &gt; 3X upper limit normal ( ULN ) Symptoms severely uncontrolled diabetes Currently unstable serious cardiovascular , renal , hepatic , hematological , oncological , endocrine , psychiatric rheumatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>